| Cover Page - USD ($) | 12 Months Ended | | |
| Mar. 31, 2022 | Jul. 01, 2022 | Sep. 30, 2021 |
| Cover [Abstract] | | | |
| Document Type | 10-K/A | | |
| Amendment Flag | true | | |
| Document Period End Date | Mar. 31, 2022 | | |
| Document Fiscal Year Focus | 2022 | | |
| Document Fiscal Period Focus | FY | | |
| Trading Symbol | TYME | | |
| Entity Registrant Name | TYME TECHNOLOGIES, INC. | | |
| Entity Central Index Key | 0001537917 | | |
| Current Fiscal Year End Date | --03-31 | | |
| Entity Filer Category | Non-accelerated Filer | | |
| Entity Well-known Seasoned Issuer | No | | |
| Entity Current Reporting Status | Yes | | |
| Entity Voluntary Filers | No | | |
| Entity Interactive Data Current | Yes | | |
| Entity Shell Company | false | | |
| Entity Small Business | true | | |
| Entity Emerging Growth Company | false | | |
| Entity Common Stock, Shares Outstanding | | 172,206,894 | |
| Entity Public Float | | | $ 153,482,658 |
| Document Annual Report | true | | |
| Document Transition Report | false | | |
| Entity File Number | 001-38169 | | |
| Entity Incorporation, State or Country Code | DE | | |
| Entity Tax Identification Number | 45-3864597 | | |
| City Area Code | 212 | | |
| Local Phone Number | 461-2315 | | |
| Entity Address, Address Line One | 1 Pluckemin Way – Suite 103 | | |
| Entity Address, City or Town | Bedminster | | |
| Entity Address, Postal Zip Code | 07921 | | |
| Entity Address, State or Province | NJ | | |
| Title of 12(b) Security | Common Stock, $0.0001 par value | | |
| Security Exchange Name | NASDAQ | | |
| Auditor Name | Grant Thornton LLP | | |
| Auditor Firm ID | 248 | | |
| Auditor Location | New York | | |
| Amendment Description | This Amendment No. 1 to the Annual Report on Form 10-K (this “Amendment”) amends the Annual Report on Form 10-K for the fiscal year ended March 31, 2022 originally filed on May 25, 2022 (the “Original Filing”) by Tyme Technologies, Inc., a Delaware corporation (“TYME” or the “Company”). The Company is filing this Amendment to present the information required by Part III of Form 10-K as the Company does not anticipate filing its definitive proxy statement within 120 days of the end of its fiscal year ended March 31, 2022. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15(a)(3) of Part IV is amended to include the currently dated certifications as exhibits. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3,4, and 5 of the certifications have been omitted. Additionally, we are not including the certificate under Section 906 of the Sarbanes-Oxley Act of 2002 as no financial statements are being filed subject to the Amendment. Except as described above or as expressly noted in this Amendment, no other changes have been made to the Original Filing and this Amendment does not reflect events occurring after the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings with the Securities and Exchange Commission. On July 3, 2022, TYME entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Syros Pharmaceuticals, Inc. (“Syros”) and Tack Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Syros (“Merger Sub”). Each of the board of directors of TYME and the board of directors of Syros have approved the Merger Agreement. Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into TYME (the “Merger”), with TYME continuing as the surviving entity and a wholly owned subsidiary of Syros. At the effective time of the Merger (the “Effective Time”), each share of common stock of Tyme, par value $0.0001 per share (the “Tyme Common Stock”), issued and outstanding immediately prior to the Effective Time will be converted into the right to receive a number of shares of fully paid and non-assessable shares of common stock of Syros, par value $0.001 per share (the “Syros Common Stock”) equal to the Exchange Ratio (as defined in the Merger Agreement). The completion of the Merger is subject to the satisfaction or waiver of certain closing conditions, including the adoption of the Merger Agreement by holders of a majority of the outstanding shares of Tyme Common Stock. | | |
